Table 3.
Association of patient characteristics with raltegravir adoption by 180 days, multivariate model
| Characteristic | Odds ratio (95% CI)* |
|---|---|
| Residence | |
| Urban | 1.72 (1.09–2.70) |
| Rural | Ref |
| Age | |
| 0–40 | Ref |
| 41–50 | 3.25 (1.42–7.44) |
| 51–60 | 2.42 (1.10–5.33) |
| 61 plus | 2.95 (1.13–7.71) |
| Gender | |
| Male | 5.51 (0.68–44.9) |
| Female | Ref |
| Race/ethnicity | |
| Black | 0.85 (0.58–1.24) |
| White, non-hispanic | Ref |
| Other | 1.23 (0.59–2.53) |
| Missing | 1.64 (0.44–6.13) |
| CD4 count | |
| 0–50 | 2.04 (1.06–3.91) |
| 51–200 | 2.04 (1.11–3.75) |
| 201–350 | 1.96 (1.05–3.64) |
| 351–500 | 1.45 (0.73–2.85) |
| >500 | Ref |
| Missing | 0.43 (0.03–6.76) |
| AIDS defining illness | |
| Yes | 1.27 (0.90–1.79) |
| No | Ref |
| Substance abuse | |
| Yes | 0.32 (0.18–0.56) |
| No | Ref |
| HIV viral load | |
| 401–999 | Ref |
| 1,000–9,999 | 1.75 (1.15–2.65) |
| 10,000–99,999 | 2.92 (1.90–4.48) |
| 100,000 plus | 3.71 (2.06–6.67) |
| Years on ART | |
| <10 | Ref |
| C10 | 1.71 (1.19–2.46) |
Ref referent category